EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease

Samuel M Lee, Jose Muratalla, Marta Sierra-Cruz, Jose Cordoba-Chacon iD

Journal of Endocrinology · 23.01.2023 · 257 (1)

DOI: 10.1530/joe-22-0155 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, erschienen am 23.01.2023. Verfasst von Samuel M Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Non-alcoholic Fatty Liver Disease, Thiazolidinediones. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome proliferator-activated receptor γ (PPARγ) belongs to a family of nuclear receptors that could serve as lipid sensors. PPARγ is the target of a group of insulin sensitizers called thiazolidinediones (TZDs) which regulate the expression of genes involved in glucose and lipid metabolism as well as adipokines that regulate metabolic function in other tissues. Non-alcoholic fatty liver disease (NAFLD) has a high prevalence worldwide and is even higher in patients with obesity and insulin resistance. TZD-mediated activation of PPARγ could serve as a good treatment for NAFLD because TZDs have shown anti-fibrogenic and anti-inflammatory effects in vitro and increase insulin sensitivity in peripheral tissues which improves liver pathology. However, mechanistic studies in mouse models suggest that the activation of PPARγ in hepatocytes might reduce or limit the therapeutic potential of TZD against NAFLD. In this review, we briefly describe the short history of PPAR isoforms, the relevance of their expression in different tissues, as well as the pathogenesis and potential therapeutics for NAFLD. We also discuss some evidence derived from mouse models that could be useful for endocrinologists to assess tissue-specific roles of PPARs, complement reverse endocrinology approaches, and understand the direct role that PPARγ has in hepatocytes and non-parenchymal cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceNon-alcoholic Fatty Liver DiseaseThiazolidinedionesAnimalsMiceHepatocytesPPAR gamma

Stichwörter der Autor:innen

Cre-LoxP-knockout modelsfatty acidslivermousenuclear receptor

Substanzen

PPAR gammaThiazolidinedionesPparg protein, mouse

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, Illinois, USA.

ORCID-Profile: Jose Cordoba-Chacon

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Lee, S. M., Muratalla, J., Sierra-Cruz, M., & Cordoba-Chacon, J. (2023). Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease. Journal of Endocrinology, 257(1). https://doi.org/10.1530/joe-22-0155

Vancouver

Lee SM, Muratalla J, Sierra-Cruz M, Cordoba-Chacon J. Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease. Journal of Endocrinology. 2023;257(1). doi:10.1530/joe-22-0155

BibTeX
@article{Lee2023,
  author = {Lee, Samuel M and Muratalla, Jose and Sierra-Cruz, Marta and Cordoba-Chacon, Jose},
  title = {Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease},
  journal = {Journal of Endocrinology},
  year = {2023},
  volume = {257},
  number = {1},
  doi = {10.1530/joe-22-0155}
}
Kostenlos starten →